MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 183 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 Mkm1R5l1d3SxeHnjJGF{e2G7 M{\n[VMh|ryP NWLXdog1PzJiaB?= M1HJcmROW09? MWPJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? M{i3cFIxPTdzME[5
A431 MnO3T4lv[XOnIFHzd4F6 MXq1JO69VQ>? NV3pNnhLPSCq NGLRdJdFVVOR NWLSb5ZHW3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKt MlHrNlA2PzFyNkm=
HepG2 NUDw[YRIS3m2b4TvfIlkKEG|c3H5 NWX2[lFEOTBizszN NILLXpgzPCCq M4\pfWROW09? M1TyN3NmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> NWm0TI1EOjF{MEW5NlU>
Sk-Hep1 MmGxR5l1d3SxeHnjJGF{e2G7 MoTkNVAh|ryP MmrJNlQhcA>? NUPNRZpHTE2VTx?= MoPyV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni MmLsNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) M4f5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH3WZR[OyEQvF2= MWm1JIQ> MYHEUXNQ NG[3PINKSzVyPUCuNVQh|ryP MUeyNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+) NXzvOpFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7IfnY6OyEQvF2= NFW5Vmw2KGR? NFP4TIlFVVOR M{foO2lEPTB;MD61NkDPxE1? M1vwN|IyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) M1;JOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmzJO69VQ>? NFXCd|E2KGR? NULZeYhlTE2VTx?= MmnRTWM2OD1yLkG4JO69VQ>? M2\WXVIyOjh7Mk[3
C643 cells harbored HRAS (G13R+/−) M2XxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXZN{DPxE1? Mm\vOUBl NW\ob4dKTE2VTx?= NWCwUYdiUUN3ME2wMlI4KM7:TR?= NWD4dGtpOjF{OEmyOlc>
Hth7 cells harbored NRAS (Q61R+/−) M4[3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS5ZpNTOyEQvF2= NWT0enhYPSCm MXnEUXNQ NHTrVY9KSzVyPUSuOUDPxE1? NV64NINQOjF{OEmyOlc>
TPC1 cells harbored RET/PTC1 rearrangement M1y4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTIN{DPxE1? NUThPXVNPSCm MkLDSG1UVw>? MWfJR|UxRTBwNUmg{txO Mmm3NlEzQDl{Nke=
Hth74 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PpSFMh|ryP NEjBV|A2KGR? MXzEUXNQ M1;Yc2lEPTB;Mj6xPUDPxE1? MVyyNVI5QTJ4Nx?=
KAT18 M{T0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4R4E{KM7:TR?= MUi1JIQ> M2nRe2ROW09? NF3hTYdKSzVyPUSuOlIh|ryP NVTWWotzOjF{OEmyOlc>
SW1736 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmxNFAh|ryP NXjZSoROPSCm NYnzOYhDTE2VTx?= Mk[0TWM2OD12Nz61OkDPxE1? NIL6WJIzOTJ6OUK2Oy=>
WRO MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vB[|ExODBizszN MoTvOUBl NVizZXpZTE2VTx?= MXPJR|UxRjFyMECg{txO NYf5NGpLOjF{OEmyOlc>
TAD2 NUPHcIppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0bmIyODByIN88US=> NXrVWGdpPSCm MnP5SG1UVw>? MkXuTWM2OD5zMECwJO69VQ>? MV:yNVI5QTJ4Nx?=
LN229 NXLRcpp5SXCxcITvd4l{KEG|c3H5 MljENE42KM7:TR?= NYS4c3U4PjBiaB?= NEHIfGtFVVOR NUn0VZUzSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= MU[yNlA2PzlzNB?=
T98G M2G1TWFxd3C2b4Ppd{BCe3OjeR?= NHHCPVIxNjVizszN MVG2NEBp NY\mOJZQTE2VTx?= MYDBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? MlXzNlIxPTd7MUS=
HC11 M4[5S2Z2dmO2aX;uJGF{e2G7 MkTRNVAh|ryP MYOyOEBp NFnRcWxFVVOR MnLiTY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=> M4L2UVIzPDJ4NkKx
MOLT-4 M1LvWmN6fG:2b4jpZ{BCe3OjeR?= NWTDXGI3OTBizszN MXO0PEBp NIXPWGZFVVOR M4f5XmlEPTB;MT635qCK|ryP M{XPU|IzPjF2MkSz
CEM-R NHzkZo1EgXSxdH;4bYMhSXO|YYm= M3G5PFExKM7:TR?= NG\ZTpo1QCCq MX;EUXNQ M1HNVWlEPTB;Mz6z5qCK|ryP NFfVVoEzOjZzNEK0Ny=>
CEM-S NULZb2dZS3m2b4TvfIlkKEG|c3H5 NXPTb5pSOTBizszN MkPHOFghcA>? MVXEUXNQ Mnf6TWM2OD13LkJihKnPxE1? MlLqNlI3OTR{NEO=
MOLT-4 MUjGeY5kfGmxbjDBd5NigQ>? NH3pXnMyOCEQvF2= NV7oU2lMOjRiaB?= NGSx[nhFVVOR NEPCZnpDdG:la4OgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOnIH;mJJRp\SClZXzsJIN6[2yn NYHDNZh5OjJ4MUSyOFM>
MOLT-4 MlPTSpVv[3Srb36gRZN{[Xl? M1W2UlTjiIoQvF2= NIPWWlg1KGh? M2PsZ2ROW09? NH[4cVRKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? MX2yNlYyPDJ2Mx?=
CEM-R MUnGeY5kfGmxbjDBd5NigQ>? Moq1OQKBkc7:TR?= MlzsOEBp M3vn[mROW09? M1zZN2lv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO0RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MkfSNlI3OTR{NEO=
CEM-S MWLGeY5kfGmxbjDBd5NigQ>? M3PIPVTjiIoQvF2= NYTMSZhSPCCq MojjSG1UVw>? MonJTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{XBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz NYPGTo9[OjJ4MUSyOFM>
HepG2 cell M3XFU2tqdmG|ZTDBd5NigQ>? NHPYXo0zOCEQvF2= MWSyOEBp NIf3VIJFVVOR NI\1TppFd3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW M1PuU|I{Pzl5M{G5
HepG2 cell MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnJdng{OCEQvF2= NX3adWhnOjRiaB?= M{P4S2ROW09? MVrJcohq[mm2czDj[YxtKGe{b4f0bC=> MnTUNlM4QTd|MUm=
HepG2 cell M1y4ZmFxd3C2b4Ppd{BCe3OjeR?= M2fnXlIxKM7:TR?= MWKyOEBp M4rZS2ROW09? NFqxcopKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFH1SnYzOzd7N{OxPS=>
GEO NXnKcmprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXnOVAxKG6P NUPXOXpIPzJiaB?= MlXHSG1UVw>? Mn36TY5pcWKrdIOgZ4VtdCCpcn;3eIg> NWniO5dzOjR3OEGyN|E>
CNE-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW0ZngyOCEQvF2= MlvUPVYhcA>? MkfpSG1UVw>? MYPJR|UxRTJwOU[g{txO M2fON|I2OzN4OUK1
CNE-2 M1rWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P6SlExKM7:TR?= M2XlWVk3KGh? M3LyPWROW09? MkO3TWM2OD12LkWzJO69VQ>? NYfoc29TOjV|M{[5NlU>
HONE-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMNVAh|ryP NUPEPWNDQTZiaB?= Ml2zSG1UVw>? NXe3SXZDUUN3ME2zMlM4KM7:TR?= NGjrPG8zPTN|NkmyOS=>
SUNE-1 NED2WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\5Z|VrOTBizszN MXm5OkBp NHT3U5hFVVOR MknUTWM2OD1yLkWyJO69VQ>? MmrONlU{OzZ7MkW=
CNE-2 NIPaPW9HfW6ldHnvckBCe3OjeR?= MnXYNVAh|ryP M2O4dFQ5KGh? NEThS3pFVVOR MXXJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy MmHrNlU{OzZ7MkW=
HONE-1 Mk\TSpVv[3Srb36gRZN{[Xl? Mo[zNVAh|ryP NILoZWY1QCCq M2TydGROW09? M4eyN2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? NHzOXWYzPTN|NkmyOS=>
NEC8 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEm2OVEh|ryP NFHMN4ZUSU6JRWK=
P12-ICHIKAWA NWTrU4ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;z[mlEPTB;MD6xNVYzKM7:TR?= NIPkSnpUSU6JRWK=
MDA-MB-175-VII NGjD[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrrVItKSzVyPUCuNVM4OzhizszN NH\0[HdUSU6JRWK=
AsPC-1 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW1fnJwUUN3ME2wMlIzOTJ{IN88US=> NXPkeoFZW0GQR1XS
T47D NULC[HdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMkiyOUDPxE1? MmK2V2FPT0WU
HH NX7LeWdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknBTWM2OD1yLkOwNlg{KM7:TR?= M{Xr[HNCVkeHUh?=
MOLT-16 NIXGclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXYTWM2OD1yLkOwN|Ih|ryP NX[0e|RDW0GQR1XS
ES5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT0cFhKSzVyPUCuN|Q1PTVizszN MmjVV2FPT0WU
RS4-11 M324WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwM{S2NUDPxE1? M2e2SHNCVkeHUh?=
KARPAS-45 NIXsV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf1XIlFUUN3ME2wMlM4OzJzIN88US=> MVjTRW5ITVJ?
NCI-H720 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK2TWM2OD1yLkO3Olc6KM7:TR?= MoPPV2FPT0WU
H9 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP6VohvUUN3ME2wMlM5QDh|IN88US=> MUTTRW5ITVJ?
EFM-19 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\jTWM2OD1yLkS0NFEh|ryP MUnTRW5ITVJ?
SBC-1 NE[yfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNESwN|Uh|ryP NXjr[oJ2W0GQR1XS
A4-Fuk M{TXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTSTWM2OD1yLkS2PFY5KM7:TR?= MkfwV2FPT0WU
NCI-H1563 NYjBRo54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnryTWM2OD1yLkS4NVg6KM7:TR?= MXzTRW5ITVJ?
HCC1419 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUiyfIxjUUN3ME2wMlQ5QDl{IN88US=> NHW4fHVUSU6JRWK=
H-EMC-SS NIXXTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS0WIFyUUN3ME2wMlQ6QTN7IN88US=> M1XsU3NCVkeHUh?=
BHT-101 NWPrXVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNUK5OlEh|ryP MkDJV2FPT0WU
IGROV-1 M13PRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNUWyOFkh|ryP NGW5XmJUSU6JRWK=
HGC-27 NGXxW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe3eodKSzVyPUCuOVY4QDNizszN MmrlV2FPT0WU
MDA-MB-361 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwNUe3OlEh|ryP M2HRPHNCVkeHUh?=
KE-37 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vKOWlEPTB;MD61PFI3KM7:TR?= M1HuTXNCVkeHUh?=
HCC70 NFj5VllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonOTWM2OD1yLkW5PFI4KM7:TR?= MVHTRW5ITVJ?
LNCaP-Clone-FGC NUDDXJpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nYWWlEPTB;MD62NVA1QCEQvF2= NYDIe3FFW0GQR1XS
HAL-01 M1LwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT4UJBEUUN3ME2wMlYzOTNizszN M4nUWnNCVkeHUh?=
HT MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwNkOyN|kh|ryP NEDuVIhUSU6JRWK=
MDA-MB-415 NUXMN5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwNkO2NlYh|ryP MofSV2FPT0WU
NOS-1 M{jKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mzfWlEPTB;MD62N|czOyEQvF2= NHWwO4RUSU6JRWK=
DU-145 NFrzWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PuO2lEPTB;MD62OFc1PSEQvF2= Ml24V2FPT0WU
OCUB-M Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrkelFZUUN3ME2wMlcxQTZ4IN88US=> MkL0V2FPT0WU
VA-ES-BJ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwN{OwNlUh|ryP M2jSbHNCVkeHUh?=
J-RT3-T3-5 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwN{S0NFMh|ryP NWHjSHZ[W0GQR1XS
MOLT-4 M4\zRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHqTWM2OD1yLkiwOVgzKM7:TR?= NFnJ[VBUSU6JRWK=
NB7 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PIbmlEPTB;MD64NlQyOSEQvF2= NFTQ[YZUSU6JRWK=
L-363 NYXmdINyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonlTWM2OD1yLkizOFQzKM7:TR?= NEPtTIdUSU6JRWK=
NKM-1 M1faUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDxTWM2OD1yLki2NlU{KM7:TR?= NYXISlROW0GQR1XS
HOP-92 M3nhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XORmlEPTB;MD64O|IzOyEQvF2= MkfiV2FPT0WU
OAW-42 M4T6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWyTWM2OD1yLki4O|Ih|ryP NUi3fXNYW0GQR1XS
HuO9 NWfu[Jd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjvTWM2OD1yLkmyO|UyKM7:TR?= MlH1V2FPT0WU
MFE-280 NWXyNIJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwOU[0OlUh|ryP MnXOV2FPT0WU
EM-2 M{\xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu4SoVKSzVyPUCuPVc6OzlizszN NIOxSFBUSU6JRWK=
NCI-H520 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu0TWM2OD1yLkm4OVkzKM7:TR?= MYLTRW5ITVJ?
LB2241-RCC MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwOUm3N|Qh|ryP NXfHZ5hTW0GQR1XS
SK-NEP-1 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnVTWM2OD1zLkG0OFg2KM7:TR?= Ml61V2FPT0WU
LXF-289 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwMUexOVYh|ryP MY\TRW5ITVJ?
EPLC-272H M4PpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEWxcnBKSzVyPUGuNVczPTZizszN NWHHZWIyW0GQR1XS
COLO-684 NUDGNWYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwMkO3NlUh|ryP NHz0OIRUSU6JRWK=
ES1 NH7PPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\tUmlEPTB;MT6yOFA3PSEQvF2= NF;ydpZUSU6JRWK=
DOHH-2 NI\DRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrGc2UzUUN3ME2xMlI5OjB|IN88US=> Mo\oV2FPT0WU
CTB-1 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDGTWM2OD1zLkK4PVkh|ryP NWDmeXhHW0GQR1XS
G-401 M2TuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG1TWM2OD1zLkK5O|k2KM7:TR?= NIXUT3pUSU6JRWK=
LoVo MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PDW2lEPTB;MT6zNlU{PCEQvF2= MmLNV2FPT0WU
Ramos-2G6-4C10 NEC3V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjhNmFnUUN3ME2xMlM{PzBzIN88US=> NFLTe|NUSU6JRWK=
MFM-223 NVPZW2p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzxU2ZuUUN3ME2xMlM1PDZzIN88US=> NI\aXm1USU6JRWK=
PA-1 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7STWM2OD1zLkO1NlY2KM7:TR?= NGjWcIJUSU6JRWK=
697 NVnVU2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXiUFNKSzVyPUGuN|c3OTZizszN M3nIbnNCVkeHUh?=
QIMR-WIL M{f4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTMTWM2OD1zLkS5NVE3KM7:TR?= MXXTRW5ITVJ?
HOS MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJW2xUUUN3ME2xMlQ6PTV6IN88US=> NWf0bpRoW0GQR1XS
DMS-273 NVTQfYZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rTVWlEPTB;MT61NVk2QSEQvF2= M3\CVXNCVkeHUh?=
ME-180 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfUfoFKSzVyPUGuOVY5QTFizszN MVHTRW5ITVJ?
HCC2218 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m1bWlEPTB;MT62PFIzPSEQvF2= Mnr0V2FPT0WU
CAL-54 M17xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z0emlEPTB;MT63NVI1OiEQvF2= MlzyV2FPT0WU
OMC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGxdmxKUUN3ME2xMlc1Pjd5IN88US=> NHPDe3RUSU6JRWK=
COR-L105 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XWUmlEPTB;MT63PVc{PyEQvF2= Mm\2V2FPT0WU
BV-173 NHroTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwOEGwO|Qh|ryP NXj2U4xnW0GQR1XS
RKO NHT6NZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnOcmVKSzVyPUGuPFcyODFizszN NIXyU41USU6JRWK=
SNU-387 NXTCfWlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDSTWM2OD1zLki4OFA3KM7:TR?= Mn3NV2FPT0WU
SW1088 M33zcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\VOmlEPTB;MT65OFYxPiEQvF2= NFm2TnhUSU6JRWK=
Hs-578-T M3y1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJwMUG0N|Mh|ryP M3rnbXNCVkeHUh?=
OC-314 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\nTWM2OD1{LkG1NFg3KM7:TR?= NWTVOoxwW0GQR1XS
RMG-I NVXJ[5NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTmUJZuUUN3ME2yMlE3Ozl6IN88US=> NED2[YxUSU6JRWK=
NCI-H1395 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[1bGJKSzVyPUKuNVgxQTFizszN NF\J[pdUSU6JRWK=
GAMG NFLm[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPYTWM2OD1{LkKzPFQ2KM7:TR?= NV3sTnZUW0GQR1XS
LB1047-RCC MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnFOGVKSzVyPUKuNlQ{OTdizszN M4P4OnNCVkeHUh?=
MN-60 NYTrZ3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG1TWM2OD1{LkK5PVI{KM7:TR?= MoLLV2FPT0WU
OAW-28 NIDETJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jqOmlEPTB;Mj6yPVk2OSEQvF2= NXfJd5NvW0GQR1XS
NCI-H2228 M{PIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHmXpRZUUN3ME2yMlMyPTV{IN88US=> MlPlV2FPT0WU
ABC-1 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwM{OyOVMh|ryP NH7sUJNUSU6JRWK=
LS-513 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\JdG5kUUN3ME2yMlM{PDh2IN88US=> NIniVmNUSU6JRWK=
KS-1 NYS3UFR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJwM{ixPVEh|ryP MWXTRW5ITVJ?
NB69 NEfR[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJwM{i5PFMh|ryP M3jqN3NCVkeHUh?=
VM-CUB-1 NHS0dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPxU5VKSzVyPUKuN|kxQDNizszN NYKxSGd[W0GQR1XS
D-423MG NV\pXIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkntTWM2OD1{LkSxNFQ1KM7:TR?= M1XBW3NCVkeHUh?=
EW-18 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTuT|h{UUN3ME2yMlQyQTN7IN88US=> MnjUV2FPT0WU
YH-13 NFLibIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwNE[xOVMh|ryP NHGyeVJUSU6JRWK=
T-24 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDJfJZCUUN3ME2yMlQ4QDhzIN88US=> NXLWXI0zW0GQR1XS
ES8 NHnkNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHYTWM2OD1{LkS5Nlg4KM7:TR?= NHvsZm5USU6JRWK=
ES3 NGLFTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfrRoFKSzVyPUKuOFk4PTlizszN MXfTRW5ITVJ?
RXF393 M4DpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUna[HcxUUN3ME2yMlYxPDh5IN88US=> MWjTRW5ITVJ?
RPMI-8226 NEK2enBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX5WllwUUN3ME2yMlYzQTV|IN88US=> NWjX[I57W0GQR1XS
AGS NYq1bWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO1bXdKSzVyPUKuO|IyOzdizszN MVjTRW5ITVJ?
HCC1395 NFS4O5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwN{WxPFch|ryP MWrTRW5ITVJ?
MV-4-11 NV;Xb25xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXVUJRJUUN3ME2yMlc2OjZ4IN88US=> NGfBbFRUSU6JRWK=
A204 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHkTWM2OD1{LkizPFczKM7:TR?= Ml;1V2FPT0WU
MCF7 M3fIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvWTWM2OD1{Lki2NVE4KM7:TR?= NITEcJBUSU6JRWK=
SNU-423 NX7CeWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwOEmyOFIh|ryP MWXTRW5ITVJ?
NCI-H1048 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nDfWlEPTB;Mj65Olg3PSEQvF2= MUHTRW5ITVJ?
GR-ST NIW3dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M165R2lEPTB;Mz6wOFYyOSEQvF2= NGfX[21USU6JRWK=
EoL-1- NIPGTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXkTWM2OD1|LkC3NFU5KM7:TR?= MXrTRW5ITVJ?
HuH-7 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojFTWM2OD1|LkC5OFY1KM7:TR?= M33KdnNCVkeHUh?=
OS-RC-2 NH3SNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX24coVIUUN3ME2zMlEyOTlizszN NVPUc45pW0GQR1XS
EW-3 M{\1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPBV4xKSzVyPUOuNVk2OjlizszN M{PNOnNCVkeHUh?=
NCI-H747 NVqyXWpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33xZmlEPTB;Mz6yNFY6PCEQvF2= NWnIUYRJW0GQR1XS
EW-16 M1XGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL2TWM2OD1|LkKxPFc6KM7:TR?= NFHjPYNUSU6JRWK=
DOK NVvxeoQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXQWItKSzVyPUOuNlI5PTlizszN NX\aT3dCW0GQR1XS
HCC2157 NGf2eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfaTWM2OD1|LkO4NVc6KM7:TR?= NETSb2VUSU6JRWK=
OVCAR-3 M3TGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLvZoVKSzVyPUOuOFA4QDZizszN NI\TSYFUSU6JRWK=
NCI-H1623 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvMXohKSzVyPUOuOFEzOjRizszN MUXTRW5ITVJ?
H4 NIDhO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfSTWM2OD1|LkS1OlI3KM7:TR?= MmSwV2FPT0WU
SW1710 NHrlT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTvN|hKSzVyPUOuOFY3PzhizszN NXrPR5FXW0GQR1XS
RT-112 NEjv[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwNUKzPFgh|ryP NVvQbpZkW0GQR1XS
DMS-114 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXHTWM2OD1|Lk[yNlc5KM7:TR?= NXTXeWNmW0GQR1XS
AN3-CA NYW3PWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNwNkK0OVYh|ryP M1jSNnNCVkeHUh?=
KNS-62 NXjqU2luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHSTWM2OD1|Lk[zN|M5KM7:TR?= NWHwc3RrW0GQR1XS
SJRH30 NXfl[3J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK2[W9KSzVyPUOuOlkyOjJizszN NUnJc5d[W0GQR1XS
G-402 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTNwN{C3NVEh|ryP NI\6NXVUSU6JRWK=
MHH-PREB-1 NX:0U2xIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jZNGlEPTB;Mz63NlA{QCEQvF2= M{f3UHNCVkeHUh?=
P30-OHK NFTERWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPhTWM2OD1|LkiwPVc3KM7:TR?= NGL3[2FUSU6JRWK=
RVH-421 NYPO[|lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D4VWlEPTB;Mz64NVc5QCEQvF2= MkfVV2FPT0WU
LU-134-A MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;qXlhKSzVyPUOuPFg1OjhizszN M3jFdnNCVkeHUh?=
ECC10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLCUo9KSzVyPUOuPVM3OjJizszN MU\TRW5ITVJ?
TGW NVzNdlVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrITWM2OD12LkCyN|A2KM7:TR?= NYHjNId{W0GQR1XS
MLMA NUjRfGZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknLTWM2OD12LkCyPVY3KM7:TR?= M4mzXXNCVkeHUh?=
SCC-25 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLHVZc1UUN3ME20MlA3PTZ4IN88US=> M4r3RXNCVkeHUh?=
TYK-nu NVPvXmVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfxVoppUUN3ME20MlA6PTN2IN88US=> M3zHU3NCVkeHUh?=
LAMA-84 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu4TWM2OD12LkG0NVkyKM7:TR?= MXTTRW5ITVJ?
Calu-3 M1LSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzBOZp7UUN3ME20MlI1PDF4IN88US=> NGLQVJNUSU6JRWK=
NCI-H460 NIT6[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTRwMk[0OFMh|ryP M3fCVnNCVkeHUh?=
EGI-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfhRlBuUUN3ME20MlM4Pzd6IN88US=> NHnL[lZUSU6JRWK=
NCI-H292 NYrBTXczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljPTWM2OD12LkO4NVQ3KM7:TR?= MXjTRW5ITVJ?
HCE-T Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGx[XlKSzVyPUSuOFE2PzlizszN MXXTRW5ITVJ?
EW-11 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLsTWM2OD12LkSxPFM5KM7:TR?= MWDTRW5ITVJ?
ATN-1 M{fl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHiTWM2OD12LkS0N|A1KM7:TR?= NETw[nBUSU6JRWK=
NB5 NH\PdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjrTWM2OD12LkWzOlk4KM7:TR?= NFr0SI9USU6JRWK=
KLE NV34OZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTRwN{CxPVgh|ryP NI\pe|NUSU6JRWK=
CAL-39 NI\h[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHETWM2OD12LkeyNVQ3KM7:TR?= NEOzbmRUSU6JRWK=
TI-73 NGq3cJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjLTWM2OD12LkiwOlA6KM7:TR?= MXPTRW5ITVJ?
HO-1-N-1 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\TbGh7UUN3ME20Mlk1OiEQvF2= NEfaXHlUSU6JRWK=
786-0 NWDONmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LYT2lEPTB;ND65OFY4OyEQvF2= NXn5[otvW0GQR1XS
SK-N-DZ MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn3RlBLUUN3ME20Mlk3OTR{IN88US=> M4P3S3NCVkeHUh?=
NCI-H446 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M335emlEPTB;NT6yNFAxQSEQvF2= NHLRXGtUSU6JRWK=
ETK-1 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPVUGZrUUN3ME21MlIyOTZ3IN88US=> MWXTRW5ITVJ?
BT-20 NFnaSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHkPJhKSzVyPUWuNlE{PTNizszN NWW5[JVVW0GQR1XS
MEL-HO NXTPOGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\Zc2lEPTB;NT6zO|M{PiEQvF2= MXPTRW5ITVJ?
CAL-27 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK1TWM2OD13LkS2N|M6KM7:TR?= NEPONmtUSU6JRWK=
SW872 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M134WmlEPTB;NT61PVQzQCEQvF2= M2HHOXNCVkeHUh?=
RPMI-2650 M1nzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTVwNk[xPVkh|ryP NWHL[JB3W0GQR1XS
PFSK-1 NGn3eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrFNHhKSzVyPUWuO|I4OzJizszN M1LqSnNCVkeHUh?=
SF295 NUXVe2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDiZ3F6UUN3ME21MlgxPjN|IN88US=> NH31S|ZUSU6JRWK=
Becker NIL0XYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDNTWM2OD13Lki2OFczKM7:TR?= MVPTRW5ITVJ?
Saos-2 M4HkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfLTWM2OD13Lki2OVMh|ryP MoHuV2FPT0WU
SK-OV-3 NXHo[lR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTVwOUm4NVYh|ryP MX3TRW5ITVJ?
VMRC-RCZ NFzKR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jl[GlEPTB;Nj6wPFc4OyEQvF2= NIrZR2VUSU6JRWK=
EW-22 M2rrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCyTWM2OD14LkG5OlQ6KM7:TR?= M2rlfnNCVkeHUh?=
BT-474 M1jzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTZwMkOzJO69VQ>? NVXGZ41VW0GQR1XS
BFTC-909 NEniNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOzcW5KSzVyPU[uN|A{PDVizszN MofFV2FPT0WU
NB12 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\YZ2lEPTB;Nj6zPVA4OSEQvF2= MVvTRW5ITVJ?
D-263MG NGq2c4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\QOINKSzVyPU[uOFUyPjlizszN MYHTRW5ITVJ?
SNB75 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvQTWM2OD14Lk[wNVQ{KM7:TR?= MX\TRW5ITVJ?
A704 M2HCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD1TWM2OD14Lk[zNFYh|ryP MmXnV2FPT0WU
NCI-H1693 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZwNkO2NFQh|ryP MofSV2FPT0WU
LN-405 NXTrbHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\mSVJKSzVyPU[uO|k3PzJizszN NF;VO|BUSU6JRWK=
CHL-1 M33lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W4R2lEPTB;Nj64NFA4QSEQvF2= M3XVVXNCVkeHUh?=
A498 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTZwOEG5OlEh|ryP MX3TRW5ITVJ?
TE-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTZwOEO4NVch|ryP Mki0V2FPT0WU
TE-6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKxVppKSzVyPU[uPVMxOzhizszN MmDoV2FPT0WU
AU565 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInC[ppKSzVyPU[uPVY6PTdizszN NF\mSIZUSU6JRWK=
RD M3TBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTZwOUiyPFQh|ryP NFLBNGVUSU6JRWK=
SW1463 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnzU2VKSzVyPUeuNVEyPjhizszN MV\TRW5ITVJ?
LU-99A MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33DemlEPTB;Nz6xOFMzOiEQvF2= NGHEcoNUSU6JRWK=
NCI-H28 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof2TWM2OD15LkK5NlQh|ryP M1jqbXNCVkeHUh?=
MC-IXC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\lTWM2OD15LkS4OVc3KM7:TR?= MXTTRW5ITVJ?
GP5d NUnVT|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTdwNEi3OlQh|ryP Mn;TV2FPT0WU
GB-1 NGPudW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTdwNUS4NFQh|ryP M3vDOXNCVkeHUh?=
CAL-33 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdwNk[yN|Mh|ryP NVHM[|A{W0GQR1XS
MSTO-211H NVjQRXhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fnU2lEPTB;Nz62O|M{PiEQvF2= NWf6NXR2W0GQR1XS
TE-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3a[IxKSzVyPUeuO|k{OzRizszN NGnYb3pUSU6JRWK=
D-566MG NUDNepRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\hTWM2OD16LkC0OFI6KM7:TR?= MoXDV2FPT0WU
JVM-3 NYXqTI83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LLUGlEPTB;OD6xOVI3QCEQvF2= NV7MXXhmW0GQR1XS
T98G NYTvSpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2NFVSUUN3ME24MlE5ODZ5IN88US=> NFnYXGpUSU6JRWK=
HCC1954 NXjxWlFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf4cGF1UUN3ME24MlQ2OTB2IN88US=> M3jhTHNCVkeHUh?=
SF126 NXrEcZJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLkV49KSzVyPUiuOFU6OzZizszN MkDwV2FPT0WU
LB996-RCC M2L5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRThwNUOyOVch|ryP M2PaPXNCVkeHUh?=
SKG-IIIa M1PpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HQUWlEPTB;OD62N|A3QSEQvF2= NVOxSnZ5W0GQR1XS
NCI-SNU-1 M4fidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml70TWM2OD16Lk[0OlQ{KM7:TR?= NELueVBUSU6JRWK=
LB771-HNC NGqzc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRThwNkS2PVYh|ryP MkXnV2FPT0WU
SCC-4 NYn1[ohPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF34cmpKSzVyPUiuOlgzOTlizszN M{XBNnNCVkeHUh?=
CAMA-1 M{nadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzBbFlzUUN3ME24Mlc4OTR4IN88US=> NGLlfW5USU6JRWK=
D-502MG NHjSSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThwN{i2Nlkh|ryP NGj0dW1USU6JRWK=
ESS-1 NVLMT4hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjTUYVKSzVyPUiuPFg4ODRizszN M{LlO3NCVkeHUh?=
HEC-1 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\tTWM2OD16Lki5PFY3KM7:TR?= Ml;qV2FPT0WU
NB10 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTlwMEKyNlQh|ryP NEWxNoNUSU6JRWK=
8505C NF;rb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TqVmlEPTB;OT6wOFI{OiEQvF2= Mnz6V2FPT0WU
EFO-27 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO1eYNNUUN3ME25MlE3PDF{IN88US=> MX3TRW5ITVJ?
HN MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;5TWM2OD17LkG2OlI5KM7:TR?= MVnTRW5ITVJ?
DSH1 NIfRfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnMUYxwUUN3ME25MlIxQDdizszN MmjRV2FPT0WU
NBsusSR MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzmeXVYUUN3ME25MlI4PDB{IN88US=> MXnTRW5ITVJ?
LS-123 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTlwM{G3OlEh|ryP Mm\tV2FPT0WU
SHP-77 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTlwM{m5N|Uh|ryP MorjV2FPT0WU
ACN NVzHbZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PwfGlEPTB;OT61N|I4PyEQvF2= MlHVV2FPT0WU
U251 NVy2SIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r4eGlEPTB;OT62OVU1PCEQvF2= M2LqSHNCVkeHUh?=
A431 M1u4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:xTWM2OD17LkiwNlM5KM7:TR?= NHTH[XBUSU6JRWK=
5637 NETxWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrafpNKSzVyPUmuPFQ6QDRizszN NWXPVlVKW0GQR1XS
MDA-MB-157 NH7QbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzYTWM2OD17LkmyPFc5KM7:TR?= MXrTRW5ITVJ?
A101D NVPkVGs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH0S|hKSzVyPUmuPVk6PzRizszN MVzTRW5ITVJ?
YKG-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y0fGlEPTB;MUCuNlAxPiEQvF2= NELWNmFUSU6JRWK=
LAN-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLscFdCUUN3ME2xNE4zOTZ2IN88US=> M4DZPHNCVkeHUh?=
OVCAR-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDWTWM2OD1zMD6yOFM{KM7:TR?= M324SXNCVkeHUh?=
A549 NHjIb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLuPGhxUUN3ME2xNE4{QTd|IN88US=> MXfTRW5ITVJ?
no-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn6OmlKSzVyPUGwMlQ{PTNizszN NETIcHVUSU6JRWK=
SF539 NHLC[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTPPFdQUUN3ME2xNE46ODRzIN88US=> NFn4XFNUSU6JRWK=
A388 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnDZ3c4UUN3ME2xNU4{QDl5IN88US=> NETJ[|NUSU6JRWK=
DEL Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfOboFKSzVyPUGxMlQzPCEQvF2= NWH1VItvW0GQR1XS
SW954 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfjNpVKSzVyPUGxMlQ3PjhizszN NGHldWVUSU6JRWK=
TK10 NIjKfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLWbnI4UUN3ME2xNU42OjdzIN88US=> NH7n[oNUSU6JRWK=
SW756 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTzTYJFUUN3ME2xNU42Ojl2IN88US=> MYDTRW5ITVJ?
PC-3 M3naNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFzLkW3OlQh|ryP MX;TRW5ITVJ?
ONS-76 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f0VmlEPTB;MUGuOlM3KM7:TR?= MlfIV2FPT0WU
A427 NWXqdlF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PMTGlEPTB;MUGuO|A6OyEQvF2= NHTyeohUSU6JRWK=
MEG-01 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXuTWM2OD1zMT63OVA6KM7:TR?= NH;q[4tUSU6JRWK=
BB30-HNC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPtXJpLUUN3ME2xNU44QTh{IN88US=> NWrR[VEzW0GQR1XS
NCI-H1299 M1XkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOyPYlSUUN3ME2xNU45ODl|IN88US=> MkDJV2FPT0WU
GCT MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFzLkiyNlgh|ryP MoPYV2FPT0WU
D-247MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3oTWM2OD1zMT65OlY{KM7:TR?= M33B[nNCVkeHUh?=
CFPAC-1 NXzpVY1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LpfmlEPTB;MUGuPVc5OiEQvF2= MVjTRW5ITVJ?
EKVX Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fXUWlEPTB;MUKuNFMyOyEQvF2= NGCzeW5USU6JRWK=
CAL-51 NYXuW5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\hOIdKSzVyPUGyMlA4OTZizszN Mn7lV2FPT0WU
BB49-HNC NX71OWNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\lWHJKSzVyPUGyMlEyPzdizszN NWDlbVFIW0GQR1XS
RPMI-7951 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF{LkG4OVQh|ryP NXm0SYx4W0GQR1XS
RH-1 NH;1e|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvvTWM2OD1zMj6yNVg1KM7:TR?= NFjTdYNUSU6JRWK=
BCPAP NHraXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL5fFF1UUN3ME2xNk41PzR7IN88US=> NWLSbXBpW0GQR1XS
GCIY NGnWR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7JTWM2OD1zMj61NlA6KM7:TR?= M4Gyd3NCVkeHUh?=
KNS-81-FD MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF{LkW4Olkh|ryP M37qXXNCVkeHUh?=
KYSE-140 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jDemlEPTB;MUKuPFU6PSEQvF2= NELLdolUSU6JRWK=
Ca-Ski NGfwNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF{LkmwOFEh|ryP MWnTRW5ITVJ?
TGBC1TKB M2X3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7UTWM2OD1zMj65NVE2KM7:TR?= NEjGXIZUSU6JRWK=
HCC1187 M{jYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKzeVlKSzVyPUGzMlE6OTJizszN M{DobnNCVkeHUh?=
SJSA-1 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;WcopiUUN3ME2xN{4zOzJ5IN88US=> NW\neHVZW0GQR1XS
CTV-1 NVLy[FhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TYbWlEPTB;MUOuN|Q2KM7:TR?= NWfHNGNlW0GQR1XS
WM-115 M2LL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF|Lk[0PFMh|ryP NIO1fJlUSU6JRWK=
CHP-212 M3\VT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe4[ZZRUUN3ME2xN{46PzN7IN88US=> MYPTRW5ITVJ?
SCC-15 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPwTWhKSzVyPUGzMlk4PzVizszN NUPnWIxCW0GQR1XS
BPH-1 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;vcm1KSzVyPUG0MlE3PjRizszN NXfudGFiW0GQR1XS
SW780 NWP2WpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LnZ2lEPTB;MUSuOVAzPSEQvF2= MV\TRW5ITVJ?
NCI-H2291 M2C4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPtd4RKSzVyPUG0MlU5PzhizszN MWXTRW5ITVJ?
JEG-3 NE[xc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzwS5FKSzVyPUG0MlY{OjZizszN NHzSVZdUSU6JRWK=
CAL-120 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj1bWpKSzVyPUG0MlcxOjdizszN NFnLN21USU6JRWK=
NCI-H23 M3TFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PwPWlEPTB;MUSuO|k6PyEQvF2= NG\WfIJUSU6JRWK=
MS-1 M3HMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFviZmpKSzVyPUG0Mlk3OTFizszN M1zCXXNCVkeHUh?=
PC-14 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2Lkm2OVQh|ryP MnftV2FPT0WU
D-283MED NYHhVpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP6Z4pKSzVyPUG1MlAyOTFizszN M2nlc3NCVkeHUh?=
OE19 M{PxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP3NYdKSzVyPUG1MlE2PDFizszN M3exRnNCVkeHUh?=
CAS-1 NHjidHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF3LkSxPFQh|ryP NFnWRWJUSU6JRWK=
NCI-H727 NEfo[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF3LkSyNlEh|ryP M2Toc3NCVkeHUh?=
SiHa M2[5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv4[VdYUUN3ME2xOU44PTl2IN88US=> Mle4V2FPT0WU
BFTC-905 M{HDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjMTWM2OD1zNT63Olk1KM7:TR?= NV\h[I9uW0GQR1XS
MDA-MB-453 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W4OmlEPTB;MU[uNVY1OiEQvF2= MUHTRW5ITVJ?
HuP-T3 M2\FO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS0TWM2OD1zNj62N|c{KM7:TR?= NHHZc4NUSU6JRWK=
SK-LU-1 M2r1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF4Lk[5OVYh|ryP MYnTRW5ITVJ?
Detroit562 NH7NUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi4fmFmUUN3ME2xOk44OzF6IN88US=> M2fqVXNCVkeHUh?=
HCC1569 M4rUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF4LkizN|ch|ryP MljQV2FPT0WU
SK-MES-1 NVnJN3BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF4Lki0NVkh|ryP NGHCVGxUSU6JRWK=
BB65-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrpfXdlUUN3ME2xO{4xPDd7IN88US=> NV\TcZpDW0GQR1XS
LOXIMVI M1Pn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF5LkC3NFch|ryP NH;ESYZUSU6JRWK=
SW1783 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrufW1KSzVyPUG3MlEzQCEQvF2= M4TpeXNCVkeHUh?=
NH-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXLdpV6UUN3ME2xO{4{OzB|IN88US=> M3;HRnNCVkeHUh?=
UACC-257 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF5LkW1NVIh|ryP NFu1VJZUSU6JRWK=
KOSC-2 M1eySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHm[lViUUN3ME2xO{43PzV5IN88US=> NGToZVJUSU6JRWK=
KG-1 NITIdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnHelZKSzVyPUG3MlY6OzdizszN NIjnTG1USU6JRWK=
M059J NYHwfFVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\hXYNKSzVyPUG3MlcxOyEQvF2= M3zsXnNCVkeHUh?=
MHH-NB-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH5ZoNKSzVyPUG3Mlk3PzNizszN Mm[3V2FPT0WU
EW-1 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvVR|BTUUN3ME2xPE4yOzh{IN88US=> MmP1V2FPT0WU
CAL-85-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;xTWM2OD1zOD6yN|U4KM7:TR?= Mny4V2FPT0WU
639-V MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF6LkOzOVQh|ryP MUnTRW5ITVJ?
C32 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\uTWM2OD1zOD60O|I4KM7:TR?= M1rCZ3NCVkeHUh?=
KM-H2 NYr2Z2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnlVmF6UUN3ME2xPE42OjN{IN88US=> MVfTRW5ITVJ?
A253 NX;2SI9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF6LkeyPFYh|ryP MXnTRW5ITVJ?
NCI-N87 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF6LkmwNFgh|ryP NH7wUotUSU6JRWK=
8-MG-BA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF7LkC2OFYh|ryP NUj0XoFJW0GQR1XS
GI-ME-N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF7LkG1OFYh|ryP MX;TRW5ITVJ?
8305C MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX4Z5RKSzVyPUG5MlIzQDZizszN NFr2NHVUSU6JRWK=
TE-8 NVzGR2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O2VWlEPTB;MUmuN|AzPCEQvF2= NYC0WmNyW0GQR1XS
KYSE-270 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrCb2ZDUUN3ME2yNE4xOjF5IN88US=> NVzLV3hlW0GQR1XS
HL-60 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq3Z2NKSzVyPUKwMlA6PDFizszN MV\TRW5ITVJ?
Mo-T M3PlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJyLkG2OlUh|ryP MoTOV2FPT0WU
NCI-H1355 NHLI[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3IVWRsUUN3ME2yNE4{Ozd2IN88US=> NX\SNlh2W0GQR1XS
HT-1080 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDXNZFKSzVyPUKwMlU1QTdizszN M2LqV3NCVkeHUh?=
MIA-PaCa-2 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL6PFhKSzVyPUKwMlY5QDNizszN NFHqSJBUSU6JRWK=
NCI-H441 NWjlS4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXKT3djUUN3ME2yNE44Ozd7IN88US=> M1XKSHNCVkeHUh?=
LCLC-97TM1 M4\wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLZTWM2OD1{MD64NVM1KM7:TR?= MXrTRW5ITVJ?
HT-3 NI\SS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XrN2lEPTB;MkGuOVY{OSEQvF2= MlXtV2FPT0WU
22RV1 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G2dmlEPTB;MkGuOVY5PSEQvF2= MmXHV2FPT0WU
LK-2 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD5VIdKUUN3ME2yNU42QTV|IN88US=> MV3TRW5ITVJ?
CW-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq3TWM2OD1{MT62NFY6KM7:TR?= M2L5bXNCVkeHUh?=
KYSE-510 NXLNVnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfxcY9KSzVyPUKxMlYxQTVizszN NGLNUIhUSU6JRWK=
CGTH-W-1 NXrDbHZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nveGlEPTB;MkGuO|E3PiEQvF2= MmXRV2FPT0WU
NCI-H661 NFzpV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ITWM2OD1{Mj6wN|Qh|ryP NF7nZWxUSU6JRWK=
KU-19-19 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fIeGlEPTB;MkKuNVY6PyEQvF2= MoDlV2FPT0WU
NCI-H2122 M2jCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\GTGt1UUN3ME2yNk4zPDN{IN88US=> NHPXUY9USU6JRWK=
NCI-H526 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnBTWM2OD1{Mj6zPFk2KM7:TR?= MnPtV2FPT0WU
NCI-H1650 M3nScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn3NFFKSzVyPUKyMlc3PCEQvF2= MVLTRW5ITVJ?
AM-38 NITQNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4mzNmlEPTB;MkKuPFY5QSEQvF2= NWC3Z4V[W0GQR1XS
NCI-H2405 NUT4NnFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPncXdKSzVyPUKzMlI2OzNizszN Mlu2V2FPT0WU
M14 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj4[WUxUUN3ME2yN{41ODh6IN88US=> MVPTRW5ITVJ?
ES4 M4fzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LERmlEPTB;MkOuOFI{OiEQvF2= NXrHfXVlW0GQR1XS
DJM-1 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hwe2lEPTB;MkOuOVI{PCEQvF2= MUXTRW5ITVJ?
S-117 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ|Lke2OVEh|ryP M2PwPXNCVkeHUh?=
MZ2-MEL M2XCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn20TWM2OD1{Mz63O|U6KM7:TR?= Ml64V2FPT0WU
SK-MEL-2 NGHUUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ|LkixN|Mh|ryP NW\Hb3p3W0GQR1XS
HCC1806 NIHYdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ|Lki3NFkh|ryP Mo\FV2FPT0WU
NMC-G1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTreWhKSzVyPUK0MlIzOjZizszN M1jjbXNCVkeHUh?=
DK-MG Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLzTWM2OD1{ND6yPVQh|ryP M1PhWnNCVkeHUh?=
SK-N-FI NH[1fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj5Wm9KSzVyPUK0MlM{ODJizszN MmXyV2FPT0WU
KINGS-1 MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLrZ3R{UUN3ME2yOE41QDd2IN88US=> NFjEc3ZUSU6JRWK=
HCC2998 NETsWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJ2LkS4PFUh|ryP NUPDN5BYW0GQR1XS
ALL-PO NEXuR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ2Lk[xPUDPxE1? NFyxZlRUSU6JRWK=
MPP-89 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT3TWM2OD1{NT6wOFU5KM7:TR?= MWHTRW5ITVJ?
NCI-H2342 M4m0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{POSGlEPTB;MkWuNVk2OyEQvF2= MUnTRW5ITVJ?
TE-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXBW4pnUUN3ME2yOU4{PTZ|IN88US=> MlzRV2FPT0WU
RH-18 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ3LkW5NVgh|ryP MVXTRW5ITVJ?
HT-1376 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq2TWM2OD1{NT62OFY2KM7:TR?= Mkf4V2FPT0WU
U-2-OS NGTncZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UTmRKSzVyPUK1MlY5QDhizszN M{XC[XNCVkeHUh?=
BT-549 NVK1T2U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\FTWM2OD1{NT65NFEyKM7:TR?= NGrmfIFUSU6JRWK=
NCI-H1755 NHzoe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fyXGlEPTB;MkWuPVk1PSEQvF2= MWnTRW5ITVJ?
EW-13 NGPqPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHsTWM2OD1{Nj6wNlc1KM7:TR?= NH\TUmtUSU6JRWK=
NB13 NX7VXm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P3d2lEPTB;Mk[uNFk1QSEQvF2= NEHmSo1USU6JRWK=
NUGC-3 NH\TZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW3TWM2OD1{Nj6yNVA{KM7:TR?= NF7teFhUSU6JRWK=
GMS-10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vQZmlEPTB;Mk[uNlM2OyEQvF2= M3rJfnNCVkeHUh?=
CHP-134 NVjaRVRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX5TWM2OD1{Nj6zPFY4KM7:TR?= MkfBV2FPT0WU
SW962 M4Dx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLTTWM2OD1{Nj61NFIyKM7:TR?= NUX3[GhkW0GQR1XS
SNU-449 NH75[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXNe|dKSzVyPUK3MlA5ODNizszN M1H0OXNCVkeHUh?=
HuP-T4 NGrsZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT0UGRLUUN3ME2yO{4xQDd7IN88US=> M1HkUHNCVkeHUh?=
SW948 NHTDWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTaTWM2OD1{Nz6xN|Q1KM7:TR?= NIPXdVBUSU6JRWK=
NCI-H226 NYqwNno5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ5LkS1O|gh|ryP MnjnV2FPT0WU
SK-PN-DW M3G4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi4ZphKSzVyPUK3MlYxOTJizszN MmXRV2FPT0WU
GI-1 NIe1UmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPsXmRbUUN3ME2yO{44OjFizszN MmTJV2FPT0WU
CAL-12T NIjtVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ6LkGxNVIh|ryP MWfTRW5ITVJ?
YAPC M{TJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXviVFdkUUN3ME2yPE4zPTZ2IN88US=> M4\WO3NCVkeHUh?=
SNU-C2B NXr4SW9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ6LkK5OlQh|ryP M{L1SnNCVkeHUh?=
RCC10RGB M37sSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ6LkW0NVch|ryP Mk\OV2FPT0WU
ES7 NGDRdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLPSG5KSzVyPUK5MlE1PjVizszN Mof0V2FPT0WU
PANC-03-27 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ7LkS0OEDPxE1? M2HMU3NCVkeHUh?=
ES6 NUPlZY14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTqV4JKSzVyPUK5MlgyPTdizszN M33YbXNCVkeHUh?=
HT-1197 NESycmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojOTWM2OD1|MD6wOVk5KM7:TR?= NWfWW3ZHW0GQR1XS
ZR-75-30 NULZW|ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojaTWM2OD1|MD6yN|g{KM7:TR?= M2PtXXNCVkeHUh?=
DB Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rD[2lEPTB;M{CuOFk1OiEQvF2= MkDPV2FPT0WU
OCI-AML2 NW[1cpRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13OcGlEPTB;M{GuNFY6KM7:TR?= MYHTRW5ITVJ?
NCI-H2170 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rad2lEPTB;M{GuPFUyPiEQvF2= MXnTRW5ITVJ?
IST-MES1 NEPXd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Tj[GlEPTB;M{KuNlg6PyEQvF2= NXHFTVg3W0GQR1XS
769-P NU\NXlVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;iTWM2OD1|Mj6zOlQyKM7:TR?= MXTTRW5ITVJ?
COR-L23 NWjlfnNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS2So82UUN3ME2zNk46ODd|IN88US=> NEHkOGlUSU6JRWK=
SW626 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX1TWM2OD1|Mz6xO|c3KM7:TR?= M3vDe3NCVkeHUh?=
LU-139 NVS4cYpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLZTWM2OD1|Mz62OlA2KM7:TR?= NUTUfmtEW0GQR1XS
HT-144 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13LXGlEPTB;M{OuPFY{KM7:TR?= MnXLV2FPT0WU
CaR-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPRZoV2UUN3ME2zN{46QDJ{IN88US=> MYTTRW5ITVJ?
OE33 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWzWYhWUUN3ME2zOE4zQDV3IN88US=> MmqxV2FPT0WU
COLO-800 NIrkV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f5V2lEPTB;M{SuN|Y1PyEQvF2= MkW2V2FPT0WU
NB14 NUXVV|l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTITWM2OD1|ND60Olg1KM7:TR?= NUTEfo9CW0GQR1XS
KURAMOCHI MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nSOGlEPTB;M{[uNVE6QCEQvF2= MYLTRW5ITVJ?
SW48 NXPWPJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j0c2lEPTB;M{[uNlQ4PCEQvF2= M3fMOXNCVkeHUh?=
Daoy M3v1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPjcGlKSzVyPUO2MlY2OzhizszN NY\4RXV{W0GQR1XS
TGBC24TKB NVjROZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPZcVFPUUN3ME2zOk43PyEQvF2= NFvLRXBUSU6JRWK=
DU-4475 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN4LkmwN|Mh|ryP MVHTRW5ITVJ?
SW1417 NXzxWGtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PZ[2lEPTB;M{iuNFU2OiEQvF2= NGTicZNUSU6JRWK=
EFO-21 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN6LkmzOFkh|ryP NHf6WplUSU6JRWK=
MG-63 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH6RpNKSzVyPUO5MlM1OjRizszN MX\TRW5ITVJ?
LC-2-ad NGDzeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLyOHBKSzVyPUO5MlU2OTJizszN MoC1V2FPT0WU
NOMO-1 M2nXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTN7LkiyO|Qh|ryP NWH5ZoQ3W0GQR1XS
COLO-741 NFjiVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnHSotKUUN3ME20NE4yOzB2IN88US=> Ml;GV2FPT0WU
BxPC-3 NFjXU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIezcVJKSzVyPUSwMlU3QDZizszN NHr4UGRUSU6JRWK=
HSC-2 NHmzU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTRyLkmxNVMh|ryP MV7TRW5ITVJ?
UMC-11 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DxUGlEPTB;NEGuNlY{KM7:TR?= MlPaV2FPT0WU
HCC1937 NF62OoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTR{Lke4OFMh|ryP MmTrV2FPT0WU
Calu-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTZS5puUUN3ME20N{4zOzh{IN88US=> NELUU4lUSU6JRWK=
NCI-H1573 M2[xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fSdWlEPTB;NEOuN|Q4PyEQvF2= NYXnOolVW0GQR1XS
SK-N-AS M2LlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTR|Lk[wNVkh|ryP NGjiXnNUSU6JRWK=
PSN1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwRmlEPTB;NEWuNlU1QCEQvF2= MkTOV2FPT0WU
TE-11 NFTlNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v5dGlEPTB;NEWuOFg1OiEQvF2= MUnTRW5ITVJ?
NCI-H1155 NEPze|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fDUWlEPTB;NEWuPFk3PyEQvF2= NE\1PXJUSU6JRWK=
KM12 NH7nRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHoNoVKSzVyPUS1MlkxPzZizszN NE\oZZBUSU6JRWK=
RO82-W-1 M{T0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfZbXpKSzVyPUS2Mlk5OjJizszN NIHqbpFUSU6JRWK=
SW1573 NEOyUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDPTm1KSzVyPUS3MlM4OzZizszN M33GWHNCVkeHUh?=
CAKI-1 M2[3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\GVGlEPTB;NEiuNlg1PSEQvF2= MkmzV2FPT0WU
U-118-MG NXe0XlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln0TWM2OD12OD6zO|AzKM7:TR?= MlXkV2FPT0WU
KYSE-520 NF7JU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HXOGlEPTB;NEiuOFAyPiEQvF2= Mlj6V2FPT0WU
HT55 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDZZmZKSzVyPUS5MlE1PzRizszN NVzMOmRuW0GQR1XS
ChaGo-K-1 NGP4PZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj5NVFqUUN3ME20PU41Pzl|IN88US=> MWHTRW5ITVJ?
IA-LM NITYbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;1V4NKSzVyPUW0MlY{OjJizszN M4e0PXNCVkeHUh?=
UACC-62 NXPHUZVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDIO|dKSzVyPUW1MlExPDZizszN NXT4SoxOW0GQR1XS
MKN7 NF7HNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HBfWlEPTB;NU[uNFI5PSEQvF2= M3P5dHNCVkeHUh?=
HPAF-II NWLYT3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjnZXl{UUN3ME21Ok41ODd|IN88US=> NV20[Y53W0GQR1XS
NTERA-S-cl-D1 NUTlVJdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrWTWM2OD13Nz63O|gh|ryP NIDrNmZUSU6JRWK=
FTC-133 M1LHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTV6LkC5Olkh|ryP NGrJ[4hUSU6JRWK=
MHH-ES-1 NIXQSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTV6LkS4NVQh|ryP MoPjV2FPT0WU
JVM-2 M4GwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;LTWM2OD13OD65OVA3KM7:TR?= MoLpV2FPT0WU
TCCSUP NI\jepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrHXHRGUUN3ME21PU42Ojd7IN88US=> NGnxbopUSU6JRWK=
COLO-824 NWG1O4J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZyLkC3NVkh|ryP M17mN3NCVkeHUh?=
647-V M1u1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG5e2FKSzVyPU[wMlE{PDdizszN NEDOO4FUSU6JRWK=
HD-MY-Z NIPkVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHm[WhKSzVyPU[wMlUzQTRizszN M17XfnNCVkeHUh?=
LS-411N M17JRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLzTWM2OD14MT6zPVA{KM7:TR?= MVvTRW5ITVJ?
NCI-H596 NFXISplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTUSmpnUUN3ME22Nk44PDl4IN88US=> NYfWO|FCW0GQR1XS
C-33-A NY\NcnNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTZ2LkC5OVch|ryP NHS1TY1USU6JRWK=
BHY MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;XRmlEPTB;NkSuNVI1PSEQvF2= NFj6WZRUSU6JRWK=
KGN NEPYOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml61TWM2OD14ND61OVE1KM7:TR?= MWTTRW5ITVJ?
NCI-H1092 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTZ3LkCwPVUh|ryP Mn;CV2FPT0WU
MZ1-PC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLVN5FnUUN3ME22OU42PjR7IN88US=> MWTTRW5ITVJ?
LB831-BLC NWHNZpE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzOWIdKSzVyPU[1Mlg1QDFizszN NXrXbW1kW0GQR1XS
SW620 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTZ4LkKwN|kh|ryP MVrTRW5ITVJ?
HuO-3N1 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELweXNKSzVyPU[4MlMzOzhizszN M2LCO3NCVkeHUh?=
SK-HEP-1 NFPYXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHiyepdKSzVyPU[5Mlk1QDZizszN NUf5So9zW0GQR1XS
LCLC-103H NHXsTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ycGhKSzVyPUewMlY4ODVizszN NX;TNWJ5W0GQR1XS
KYSE-70 M4WwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;IcmlEPTB;N{CuO|g{PSEQvF2= MnnsV2FPT0WU
Mewo M2W0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfQWJdKSzVyPUexMlUxPSEQvF2= M2HSOnNCVkeHUh?=
COLO-668 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3sTWM2OD15MT64OFUyKM7:TR?= NFrNZWVUSU6JRWK=
NCI-H522 NFLzRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInMV3VKSzVyPUeyMlM1OTNizszN MmnVV2FPT0WU
NCI-H1437 NGrxeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTd2LkSwOFgh|ryP M2\4d3NCVkeHUh?=
U-266 NFHpN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf6Xm5KSzVyPUe1MlQ2OTZizszN M1;uOHNCVkeHUh?=
MC116 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTd3LkW3NFgh|ryP MXTTRW5ITVJ?
PANC-10-05 M2KyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn2TWM2OD15Nz60NlQ{KM7:TR?= MUnTRW5ITVJ?
KYSE-180 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjaUoJKSzVyPUe3MlU1PTRizszN NXnBNHVXW0GQR1XS
JAR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTd7LkC1OFYh|ryP NXTqU4llW0GQR1XS
CAL-62 NHzPXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CxZ2lEPTB;OECuNFk2KM7:TR?= MnvFV2FPT0WU
A3-KAW NF22N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC3dnJuUUN3ME24NE4zOTV2IN88US=> MYXTRW5ITVJ?
PANC-08-13 M17ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nIc2lEPTB;OEGuNVc3QCEQvF2= NG\D[ZVUSU6JRWK=
HSC-3 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T5O2lEPTB;OEOuN|A4OSEQvF2= M3zlfXNCVkeHUh?=
HTC-C3 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjGTWM2OD16Mz60O|AzKM7:TR?= M4CycXNCVkeHUh?=
KY821 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj1TWM2OD16ND6wPFkzKM7:TR?= MkH0V2FPT0WU
DoTc2-4510 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv6TWM2OD16ND6yNVg2KM7:TR?= MkXpV2FPT0WU
NCI-H1581 M1;GTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTh3LkS2OFEh|ryP M1q3cHNCVkeHUh?=
KARPAS-299 NYjwVWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPFTWM2OD16Nj6xPVc4KM7:TR?= NGfDNm5USU6JRWK=
IST-MEL1 NIrWXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOxWoZHUUN3ME24Ok45QDd{IN88US=> NWL0dmNWW0GQR1XS
KP-N-YS NXW4cIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTh7LkmwNlgh|ryP M1\PXnNCVkeHUh?=
KYSE-410 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLsTWM2OD17MT60NFQzKM7:TR?= MlGxV2FPT0WU
TE-10 NIXBXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES4fmtKSzVyPUmxMlU3OTFizszN NV7iPYlpW0GQR1XS
SK-MEL-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTl{LkmxNFYh|ryP NFXRXIpUSU6JRWK=
COLO-792 NGnZZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;wXmlEPTB;OUWuNlU3PCEQvF2= MX7TRW5ITVJ?
SCH MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDqTWM2OD17Nj6zPFc4KM7:TR?= MWrTRW5ITVJ?
NCI-H1792 NWL5Wo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LkOWlEPTB;OU[uPFk6OiEQvF2= MYjTRW5ITVJ?
NCI-H2029 M3T2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWwVZVVUUN3ME25Ok46PTZ4IN88US=> MnfKV2FPT0WU
SW684 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPqTotKSzVyPUm4MlY3PTRizszN M363[HNCVkeHUh?=
NCI-H209 M{K4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFyMD6xNlEh|ryP M3zJW3NCVkeHUh?=
HLE NELsc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\STWM2OD1zMEWuNlgzKM7:TR?= NGfK[|FUSU6JRWK=
GOTO NYPaRW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\iZ49WUUN3ME2xNFcvPzd5IN88US=> M2TrZnNCVkeHUh?=
NCI-H1793 NFW5VVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf5bXhKSzVyPUGwPU4zQCEQvF2= NU\FTpd6W0GQR1XS
D-392MG NH:0XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHtPY1UUUN3ME2xNVcvOzl6IN88US=> NUSxV4ZyW0GQR1XS
SW1990 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXrTWM2OD1zMkCuPVUyKM7:TR?= Mo[wV2FPT0WU
ML-2 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfiZnlKSzVyPUGyNU43PzZizszN NIK1U3hUSU6JRWK=
NCI-H2452 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe0NpNGUUN3ME2xNlIvOjFizszN M1zVcXNCVkeHUh?=
SK-MEL-30 M37Kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[2dYRSUUN3ME2xNlMvOjR2IN88US=> NGTzZ2NUSU6JRWK=
SN12C NWXqbpdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF{ND6xO|Yh|ryP NYLWc5ZQW0GQR1XS
NCI-H1770 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF{NT61NVQh|ryP NEnkW41USU6JRWK=
SF268 NV62ZotUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fNcmlEPTB;MUK2MlE2QCEQvF2= NFrvb4tUSU6JRWK=
BALL-1 M2fQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF{Nj6yN{DPxE1? M2GxXnNCVkeHUh?=
COLO-679 NFPUT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWyTWM2OD1zMk[uO|U{KM7:TR?= MWrTRW5ITVJ?
A2780 NHzYemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF{OD65PFgh|ryP M2jQRnNCVkeHUh?=
NCI-H1651 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0TWM2OD1zM{GuNlQ{KM7:TR?= MoHQV2FPT0WU
NCI-H2087 NF[1epBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF|MT60PFMh|ryP M1;wO3NCVkeHUh?=
U-87-MG NXG2cGU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF|Mz62NFQh|ryP MmjlV2FPT0WU
LB2518-MEL NVOzWZdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXjWY5MUUN3ME2xN|UvQTl|IN88US=> NYfiUGU4W0GQR1XS
HCT-116 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF|Nz6yNVch|ryP NGXyTFVUSU6JRWK=
Ca9-22 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrXWJlKSzVyPUGzPU45OzNizszN M2H4ZnNCVkeHUh?=
COR-L88 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPDfHZ1UUN3ME2xOFIvOTRizszN NXuyfHY{W0GQR1XS
CP50-MEL-B M13B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX5WI14UUN3ME2xOFQvPTBzIN88US=> NHj3bmRUSU6JRWK=
OVCAR-8 M2nXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrlUnpKSzVyPUG0OU43OzZizszN M3LROnNCVkeHUh?=
SK-MEL-3 M{Hibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j2dmlEPTB;MUS3Mlg4QCEQvF2= M16zOnNCVkeHUh?=
GT3TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF2OT65Nlgh|ryP M3PZVXNCVkeHUh?=
KYSE-450 NV7RTXpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF3MT61N|kh|ryP MmPhV2FPT0WU
CAPAN-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L2VmlEPTB;MUWzMlA3PCEQvF2= NWD3VINTW0GQR1XS
BEN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorkTWM2OD1zNUOuPVI5KM7:TR?= NFOzdItUSU6JRWK=
NCI-H1304 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor3TWM2OD1zNUSuOlk1KM7:TR?= MmXkV2FPT0WU
KU812 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF3OD62O|Qh|ryP MV7TRW5ITVJ?
Capan-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvtV5hKSzVyPUG2NE42PTNizszN MX;TRW5ITVJ?
A673 M1HpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq0TpFKSzVyPUG2NU44ODVizszN M1\hOXNCVkeHUh?=
SAS Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTpTWM2OD1zNkKuOlc5KM7:TR?= MkXNV2FPT0WU
NY NVf6VpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnrN21KSzVyPUG2OU4{OTRizszN NYnrXol1W0GQR1XS
HCE-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHZ[WdrUUN3ME2xOlYvQDR3IN88US=> MVjTRW5ITVJ?
MDA-MB-231 M3WyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPkTWM2OD1zN{euOVA{KM7:TR?= MofXV2FPT0WU
no-10 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3XTWM2OD1zN{iuNVM1KM7:TR?= MkL6V2FPT0WU
MZ7-mel NXrmcGVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDK[mxTUUN3ME2xO|gvPDZ5IN88US=> MmDqV2FPT0WU
NCI-H82 NFr3SFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7iZnJ1UUN3ME2xPFAvOTZ3IN88US=> MmLtV2FPT0WU
CAL-72 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X3WGlEPTB;MUi1MlA2PCEQvF2= Mn7aV2FPT0WU
NCI-SNU-5 M3zhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\pTWM2OD1zOE[uPFQh|ryP MY\TRW5ITVJ?
OVCAR-4 NGDDSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LKNGlEPTB;MUi4MlM{OyEQvF2= Mn;0V2FPT0WU
SCC-9 M2D0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHMTWM2OD1zOUGg{txO MlG5V2FPT0WU
KYSE-150 NFn0RZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHxb3hSUUN3ME2xPVEvQDh6IN88US=> MkTyV2FPT0WU
HT-29 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWGyT3Y6UUN3ME2yNFEvOjF{IN88US=> M3HKcXNCVkeHUh?=
COLO-678 NVfOd45NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorqTWM2OD1{MEGuOFUh|ryP MYrTRW5ITVJ?
NCI-H650 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJyMj6xNFMh|ryP M13ze3NCVkeHUh?=
HuCCT1 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPQT|JKSzVyPUKwOE4zODhizszN M2P5OXNCVkeHUh?=
SW1116 NG[0WmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7FTWM2OD1{MEeuNFc4KM7:TR?= MmnvV2FPT0WU
DBTRG-05MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfhN2lKSzVyPUKwO{46ODlizszN NFzidIpUSU6JRWK=
SW982 NVzn[|kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTFSWw3UUN3ME2yNFcvQTR6IN88US=> MmPHV2FPT0WU
RCM-1 NXvyfXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknaTWM2OD1{MUSuO|YzKM7:TR?= Ml3vV2FPT0WU
COLO-320-HSR M37LWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJzNj6xNlUh|ryP M{HOcHNCVkeHUh?=
KNS-42 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ToTGlEPTB;MkG2MlU4PCEQvF2= NGmzSIVUSU6JRWK=
C2BBe1 NXTYOIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jSSmlEPTB;MkOxMlkxPSEQvF2= MmWyV2FPT0WU
CCRF-CEM NHXKeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq1clBKSzVyPUK0N{44QTVizszN MUHTRW5ITVJ?
SH-4 NYPDN4U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ2Nj6wPUDPxE1? NIPCXoRUSU6JRWK=
LS-1034 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vNPWlEPTB;MkS2MlI3PiEQvF2= Ml3KV2FPT0WU
NCI-H2347 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTQem1oUUN3ME2yOFcvPzF|IN88US=> MVLTRW5ITVJ?
RPMI-8866 M2jIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor1TWM2OD1{NEmuNlch|ryP NXK2V5JtW0GQR1XS
GAK NFXNcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3TWM2OD1{NUOuNFAzKM7:TR?= MVLTRW5ITVJ?
NB6 NHrLU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrI[W5MUUN3ME2yO|AvOSEQvF2= NFnDbnhUSU6JRWK=
COLO-680N M{TVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHJTWM2OD1{N{KuOVI4KM7:TR?= MmK4V2FPT0WU
RERF-LC-MS NUPW[IRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i4RWlEPTB;Mke2MlAxPyEQvF2= NGDreGpUSU6JRWK=
TGBC11TKB Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj3OI17UUN3ME2yO|gvOTd6IN88US=> MW\TRW5ITVJ?
C8166 NUPS[HNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHrTHE5UUN3ME2yO|gvPTB4IN88US=> MmHiV2FPT0WU
HDLM-2 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzFcHJKSzVyPUK5OE41ODlizszN NF[yR3NUSU6JRWK=
IGR-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\he2lEPTB;Mkm1MlY2QSEQvF2= NX35TIQ3W0GQR1XS
FADU MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nZdmlEPTB;Mkm3MlUyKM7:TR?= M1vsSHNCVkeHUh?=
L-428 NWfsUoU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe5fWtKSzVyPUK5O{43OTZizszN M1yxfHNCVkeHUh?=
LU-65 NGLTOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\vUnluUUN3ME2zNFQvOzJizszN NGLQPXhUSU6JRWK=
HEL Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1SHVKSzVyPUOwPU46QDNizszN NX;iOZRmW0GQR1XS
NCI-H810 NFTEfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDDTWM2OD1|MUCuOVch|ryP NX\6UnlpW0GQR1XS
C3A M2S4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNzMT64NFIh|ryP NIjMcGdUSU6JRWK=
NCI-H630 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjLTWM2OD1|M{KuNlk1KM7:TR?= MmTVV2FPT0WU
KP-N-YN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy2[4hnUUN3ME2zOFEvOTJ|IN88US=> NGDCbFVUSU6JRWK=
MOLT-13 NX[zOlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3noWGlEPTB;M{SyMlMzPiEQvF2= MVLTRW5ITVJ?
NCI-H1993 NHfvSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnaPFBKSzVyPUO0Nk4{PjVizszN M{DLeXNCVkeHUh?=
BE-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTN2ND6xOlch|ryP MlzaV2FPT0WU
IST-SL1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nQeWlEPTB;M{S3MlQxOSEQvF2= MYfTRW5ITVJ?
TE-9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqzeJJKSzVyPUO2N{42QDlizszN NF3PW4NUSU6JRWK=
LU-135 NXzE[YUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PnWmlEPTB;M{[3MlA{PSEQvF2= MlzsV2FPT0WU
T84 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjONVZmUUN3ME2zO|QvPzF{IN88US=> Ml;WV2FPT0WU
K-562 MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN6Mz6zOkDPxE1? MYLTRW5ITVJ?
SBC-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTtN5M3UUN3ME2zPFYvQTh3IN88US=> M4\1dnNCVkeHUh?=
NB17 NEnBWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPaTWM2OD1|OUKuOVk3KM7:TR?= MoDXV2FPT0WU
NCI-H2052 NXPXUJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H6[2lEPTB;M{m4MlQ4OiEQvF2= NHLKZ|RUSU6JRWK=
HCC38 NWm4Ulk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPoTWM2OD12MEGuOVk{KM7:TR?= MVLTRW5ITVJ?
NCI-H69 NHf0fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnBTWM2OD12NEGuNFg{KM7:TR?= MVrTRW5ITVJ?

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01263145 Completed Adult Solid Neoplasm|Recurrent Breast Carcinoma|Stage IV Breast Cancer National Cancer Institute (NCI) January 5 2011 Phase 1
NCT01239342 Active not recruiting Metastatic Renal Cell Cancer|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer National Cancer Institute (NCI)|M.D. Anderson Cancer Center January 27 2011 Phase 2
NCT01604772 Completed Recurrent Oral Cavity Adenoid Cystic Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Adenoid Cystic Carcinoma|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 National Cancer Institute (NCI) July 23 2012 Phase 2
NCT01480154 Active not recruiting Adult Solid Neoplasm|Hormone-Resistant Prostate Carcinoma|Recurrent Melanoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 National Cancer Institute (NCI) November 23 2011 Phase 1
NCT01251861 Active not recruiting Recurrent Prostate Carcinoma|Stage I Prostate Cancer AJCC v7|Stage IIA Prostate Cancer AJCC v7|Stage IIB Prostate Cancer AJCC v7|Stage III Prostate Cancer AJCC v7 National Cancer Institute (NCI) December 23 2010 Phase 2
NCT01021748 Completed Locally Advanced or Metastatic Solid Tumors Merck Sharp & Dohme Corp.|AstraZeneca November 23 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 : AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) : Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID